



PRESS INFORMATION

WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE® (CA9-SCAN)

Embargo until 8 am (German/Belgian time) – June 6, 2008

Louvain-la-Neuve & Munich, June 6, 2008. The Munich-based biopharmaceutical company, WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard), has signed a licensing agreement with IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB / Brussels, Belgium) for the worldwide marketing, distribution and sales of its diagnostic product candidate REDECTANE® (CA9-SCAN). The agreement gives IBA the exclusive global rights and licenses required for manufacturing and marketing the product.

REDECTANE® is an imaging diagnostic designed to support physicians in diagnosing clear cell renal cell cancer prior to surgery. REDECTANE® is a radiolabelled antibody visualized by Positron Emission Tomography (PET) and is currently in a pivotal phase III registration trial. REDECTANE® should improve cancer diagnostics and the follow-up monitoring of patients. The peak sales potential of REDECTANE® is estimated to reach over US\$100 Million in the diagnosis of clear cell renal cell cancer alone.

According to the agreement, WILEX will manufacture the cold antibody and be responsible for clinical development. IBA will be responsible for manufacturing by labeling the antibody and will be responsible for distribution, sales and marketing of REDECTANE®. WILEX will receive an upfront payment, milestone payments and certain contributions-in-kind. After the planned market approval, WILEX will get 20% on ex-factory sales until a sales volume of EUR 7 million is reached. After that WILEX will get 45% on total ex-factory sales.

WILEX retains worldwide co-promotion rights and may use these to co-promote REDECTANE® amongst urologists and oncologists. The companies agreed not to disclose any further details of the agreement. IBA and WILEX had already entered into a manufacturing agreement for the ongoing Phase III registration trial in December 2006.

"We are very pleased about this commercial partnership as IBA is the ideal partner for REDECTANE®", said Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX AG. "IBA possesses both the know-how and the infrastructure necessary for developing the market for REDECTANE® rapidly and comprehensively following the product's approval. IBA already markets globally its other products to radiologists, the potential customers of REDECTANE®. We will support marketing by co-promoting the product to urologists and oncologists within our worldwide network".

Pierre Mottet, Chief Executive Officer of IBA explains: "This agreement is an important milestone in the expansion of our leading position in the field of radiopharmaceutical products. We are already the leading supplier of PET radiopharmaceuticals worldwide and this partnership agreement with WILEX confirms our strategy of offering technology, materials and services to medical imaging centers from a single source. We very much look forward to our enhanced cooperation".



About REDECTANE® (CA9-SCAN)

REDECTANE® is the diagnostic candidate CA9-SCAN, which is one of two product candidates from WILEX's late stage multi-product portfolio which is in a pivotal registration trial. REDECTANE® is a radioactively labeled form of the antibody WX-G250 and is being developed for the pre-surgical diagnosis of clear cell renal cell cancer. The labeled antibody accumulates in the tumor tissue and can be visualized by means of Positron Emission Tomography (PET). An earlier feasibility study found that a positive result with REDECTANE® was confirmed as clear cell renal cell carcinoma in 100% of the cases (positive predictive value). REDECTANE® could determine whether the patient had clear cell renal cell carcinoma before surgery and the subsequent pathology. Therefore, REDECTANE® could significantly improve and simplify treatment planning for patients suspected of having renal cancer.

About WILEX

WILEX is a biopharmaceutical Company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. WILEX's mission is to develop drugs and diagnostic agents with a low side effect profile and targeted treatment of different types of cancer as well as for early detection of tumors. WILEX's product candidates are based on antibodies and small molecules. WILEX possesses an attractive pipeline which includes both drug and diagnostic product candidates: The substances RENCAREX® and REDECTANE® are currently undergoing a Phase III registration trial. The substance WX-671 is currently in a Phase II program. Based on this pipeline, WILEX's aim is to achieve profitability within a few years through the commercialization of its products and in the long term to finance its research and development programs from its operating business.

Website: <http://www.wilex.com>

Contact

Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
email: press@wilex.com

About IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

IBA's leading role in the field of Molecular Imaging continues to grow through the constant innovation its technology is built upon, as well as through its worldwide radiopharmaceuticals distribution network. With an ever-increasing number of sites in North America, Europe and Asia, IBA continues to make radiopharmaceuticals, today mostly FDG, more accessible to hospitals and imaging centers across the world.

Website: <http://www.iba-worldwide.com>.

Contact

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
IBA
Tel.: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future



results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.